Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN – Get Free Report) rose 4% during trading on Friday . The company traded as high as $7.03 and last traded at $6.45. Approximately 21,353 shares traded hands during mid-day trading, an increase of 1,072% from the average daily volume of 1,821 shares. The stock had previously closed at $6.20.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Wednesday, April 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Stock Analysis on Addex Therapeutics
Addex Therapeutics Trading Up 4.0%
About Addex Therapeutics
Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.
The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.
Featured Stories
- Five stocks we like better than Addex Therapeutics
- Cooking Up Profits: Cracker Barrel’s Turnaround
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
